AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31553254 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing
Number of subjects: 3
Study 31553254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose EGF vs High-dose EGF
Number of subjects: 3
Study 28059565 — intervention group
Group type: EXPERIMENTAL
Intervention: message reception and expression (treatment group)
Number of subjects: 201
Study 28059565 — intervention group
Group type: COMPARATOR
Intervention: campaign message reception only (control group)
Number of subjects: 201
Study 25794236 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (MC)
Number of subjects: 16
Study 25794236 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic placebo (PLA)
Number of subjects: 16
Study 25116984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi training
Number of subjects: 66
Study 25116984 — intervention group
Group type: COMPARATOR
Intervention: Educational control intervention
Number of subjects: 66
Study 22434756 — intervention group
Group type: EXPERIMENTAL
Intervention: HFF > 5% (n = 16)
Number of subjects: 41
Study 22434756 — intervention group
Group type: COMPARATOR
Intervention: HFF ≤ 5% (n = 25)
Number of subjects: 41
Study 19075089 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 0
Study 19075089 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study 17690485 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of hop water extract (HWE)
Number of subjects: 39
Study 17690485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 15694055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular etofenamate (1 g/day)
Number of subjects: 110
Study 15694055 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular diclofenac (75 mg/day)
Number of subjects: 110
Study 11340108 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 10000
Study 11340108 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 10000
Study 11340108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000
Study 11340108 — intervention group
Group type: COMPARATOR
Intervention: Non-night blind women (all supplementation groups combined)
Number of subjects: 10000
Study 7980884 — intervention group
Group type: EXPERIMENTAL
Intervention: Home detoxification
Number of subjects: 20
Study 7980884 — intervention group
Group type: COMPARATOR
Intervention: Inpatient detoxification
Number of subjects: 20
Study 2923424 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of morphine sulphate
Number of subjects: 32
Study 2923424 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of ketamine hydrochloride
Number of subjects: 32
Study 2923424 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined continuous subcutaneous infusion of morphine sulphate and ketamine hydrochloride
Number of subjects: 32
Study 2923424 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine sulphate
Number of subjects: 32
Study 31494365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 1.0 mg/kg
Number of subjects: 60
Study 31494365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 0.5 mg/kg
Number of subjects: 60
Study 31494365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 0.1 mg/kg
Number of subjects: 60
Study 31494365 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (control)
Number of subjects: 60
Study 31073521 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnion group
Number of subjects: 89
Study 31073521 — intervention group
Group type: EXPERIMENTAL
Intervention: PDLLA group
Number of subjects: 89
Study 31073521 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 28116886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol® 100mg/day for 8 weeks
Number of subjects: 35
Study 22967997 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 228
Study 22967997 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (CBDCA/PTX)
Number of subjects: 228
Study 22967997 — intervention group
Group type: COMPARATOR
Intervention: Platinum throughout treatment
Number of subjects: 228
Study 22967997 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib, platinum, and pemetrexed (PEM) or docetaxel (DOC)
Number of subjects: 228
Study 21485669 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV (Non-invasive positive pressure ventilation)
Number of subjects: 40
Study 19272441 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 59
Study 19272441 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 59
Study 19272441 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (mental tasks)
Number of subjects: 59
Study 19272441 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest condition
Number of subjects: 59
Study 16484565 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE)
Number of subjects: 52
Study 16484565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 12627259 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (group A)
Number of subjects: 36
Study 12627259 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 36
Study 10705078 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (euglycemic hyperinsulinemic clamping)
Number of subjects: 5
Study 10705078 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (stopped after clamping)
Number of subjects: 5
Study 9159690 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (Healon)
Number of subjects: 66
Study 9159690 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% hydroxypropyl methylcellulose (Hymecel)
Number of subjects: 66
Study 9159690 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4% sodium hyaluronate (Healon GV)
Number of subjects: 66
Study 9159690 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% sodium chondroitin sulfate‐3% sodium hyaluronate (Viscoat)
Number of subjects: 66
Study 7910888 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization partograph with an agreed labour-management protocol
Number of subjects: 35484
Study 2895663 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 2895663 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 0
Study 29458931 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy program (10 sessions, once a week from April 2017 to June 2017)
Number of subjects: 28
Study 29458931 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 26660337 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity wheelchair training (30-40% heart rate reserve, twice a week, for 30 min per session)
Number of subjects: 29
Study 26660337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 29
Study 25592012 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 800 μg/d
Number of subjects: 103
Study 25592012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 23323790 — intervention group
Group type: EXPERIMENTAL
Intervention: SagaPro
Number of subjects: 69
Study 23323790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 21924547 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine alone (GEM)
Number of subjects: 44
Study 21924547 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus oxaliplatin (GEMOX)
Number of subjects: 44
Study 18438894 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity intervention
Number of subjects: 134
Study 18438894 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study 16575723 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin plus doxycycline (DG regimen)
Number of subjects: 191
Study 16575723 — intervention group
Group type: COMPARATOR
Intervention: Streptomycin plus doxycycline (DS regimen)
Number of subjects: 191
Study 14974365 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose of CyA and daclizumab (group A)
Number of subjects: 44
Study 14974365 — intervention group
Group type: COMPARATOR
Intervention: Normal dose of CyA without daclizumab (group B)
Number of subjects: 44
Study 14974365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 11045301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal urokinase (5000 IU intraluminally in the peritoneal catheter, left for 4 hours before next exchange)
Number of subjects: 80
Study 11045301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no urokinase)
Number of subjects: 80
Study 11045301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal urokinase
Number of subjects: 80
Study 11045301 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 9363911 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (4 mg/day)
Number of subjects: 24
Study 8489205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide 100 mg/day
Number of subjects: 201
Study 8489205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide 200 mg/day
Number of subjects: 201
Study 8489205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide 400 mg/day
Number of subjects: 201
Study 8489205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 3446704 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelfoam paste
Number of subjects: 100
Study 3446704 — intervention group
Group type: COMPARATOR
Intervention: Bone wax
Number of subjects: 100
Study 29203092 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.2 mg/d
Number of subjects: 225
Study 29203092 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.4 mg/d
Number of subjects: 225
Study 29203092 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 106.6 mg/d
Number of subjects: 225
Study 29203092 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate
Number of subjects: 225
Study 27486235 — intervention group
Group type: COMPARATOR
Intervention: DHEA (800 mg)
Number of subjects: 27
Study 27486235 — intervention group
Group type: COMPARATOR
Intervention: DHEA (1,600 mg)
Number of subjects: 27
Study 27486235 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 27
Study 24843051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein ablation catheter (PVAC)
Number of subjects: 188
Study 24843051 — intervention group
Group type: COMPARATOR
Intervention: Wide-area circumferential ablation (WACA)
Number of subjects: 188
Study 22892814 — intervention group
Group type: EXPERIMENTAL
Intervention: Children <6 years old
Number of subjects: 351
Study 20304278 — intervention group
Group type: EXPERIMENTAL
Intervention: TriVerse (TV) system
Number of subjects: 24
Study 20304278 — intervention group
Group type: COMPARATOR
Intervention: Molecular resonance generator (MR)
Number of subjects: 24
Study 18272323 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic medication
Number of subjects: 82
Study 18272323 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional antipsychotic medication
Number of subjects: 82
Study 18272323 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 82
Study 16179200 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized statistical method of analyzing vessel shapes from MRA
Number of subjects: 64
Study 16179200 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 64
Study 12798469 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oestradiol valerate (E(2)V) plus cyproterone acetate
Number of subjects: 149
Study 12798469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic E(2)V plus cyproterone acetate
Number of subjects: 149
Study 12798469 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined oestrogen (E(2)) plus norethindrone acetate
Number of subjects: 149
Study 12798469 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) combined with local delivery of levonorgestrel
Number of subjects: 149
Study 12798469 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)V plus medroxyprogesterone
Number of subjects: 149
Study 12798469 — intervention group
Group type: COMPARATOR
Intervention: No HRT (reference group)
Number of subjects: 149
Study 11005901 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct composite restorations
Number of subjects: 88
Study 11005901 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect composite restorations
Number of subjects: 88
Study 11005901 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect inlays
Number of subjects: 88
Study 11005901 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations in molars
Number of subjects: 88
Study 11005901 — intervention group
Group type: EXPERIMENTAL
Intervention: Premolars
Number of subjects: 88
Study 8794971 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 6
Study 8794971 — intervention group
Group type: COMPARATOR
Intervention: Osseous Surgery (OS)
Number of subjects: 6
Study 1291926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (1 tablet b.i.d. for 10 days)
Number of subjects: 50
Study 1291926 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (1 tablet b.i.d. for 10 days)
Number of subjects: 50
Study 3908879 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise (endurance training), thrice weekly for one year
Number of subjects: 88
Study 3908879 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study 31988711 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation (SM)
Number of subjects: 51
Study 31988711 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 51
Study 30001423 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based palliative approach (HPA)
Number of subjects: 27
Study 26773871 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 709
Study 26773871 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 709
Study 24148608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioembolic stroke (patients unwilling or unable to take oral anticoagulants)
Number of subjects: 1794
Study 24148608 — intervention group
Group type: EXPERIMENTAL
Intervention: Large artery atherothrombosis stroke
Number of subjects: 1794
Study 24148608 — intervention group
Group type: EXPERIMENTAL
Intervention: Small artery occlusion strokes
Number of subjects: 1794
Study 24148608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioembolic strokes
Number of subjects: 1794
Study 24148608 — intervention group
Group type: EXPERIMENTAL
Intervention: Other etiology strokes
Number of subjects: 1794
Study 24148608 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetermined etiology strokes
Number of subjects: 1794
Study 24148608 — intervention group
Group type: EXPERIMENTAL
Intervention: Index small artery occlusion stroke
Number of subjects: 1794
Study 22045231 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic techniques (total extraperitoneal technique, transabdominal preperitoneal technique)
Number of subjects: 75
Study 22045231 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (Prolene mesh graft technique)
Number of subjects: 75
Study 22045231 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgeries
Number of subjects: 75
Study 20528002 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil-based regimen
Number of subjects: 130
Study 20528002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 18518865 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen flow rate of 5 l.min(‐1)
Number of subjects: 20
Study 18518865 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen flow rate of 10 l.min(‐1)
Number of subjects: 20
Study 18518865 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen flow rate of 15 l.min(‐1)
Number of subjects: 20
Study 15950836 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual verbal instructions (IVI)
Number of subjects: 60
Study 15950836 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated asthma classes (AS)
Number of subjects: 60
Study 15950836 — intervention group
Group type: COMPARATOR
Intervention: Written information (asthma booklet, B)
Number of subjects: 60
Study 15950836 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including IVI, AS, and B)
Number of subjects: 60
Study 12735671 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) plus intravenous prednisolone (1 mg/kg)
Number of subjects: 70
Study 12735671 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prednisolone (1 mg/kg)
Number of subjects: 70
Study 12735671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 10502867 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual motion extrapolation task implemented on the Web using Java.
Number of subjects: 0
Study 8621369 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching sessions on asthma self-management principles and skills, including peak flow monitoring, conducted by school nurses for 18 children over an 8-week period.
Number of subjects: 36
Study 8621369 — intervention group
Group type: COMPARATOR
Intervention: Regular care by nurses without teaching sessions for 18 children.
Number of subjects: 36
Study 1662978 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized local anaesthetic mixture (0.5% bupivacaine 10 ml, 2% lignocaine 10 ml with adrenaline 1 in 200,000, plus 8.4% sodium bicarbonate 2 ml)
Number of subjects: 0
Study 1662978 — intervention group
Group type: COMPARATOR
Intervention: Plain local anaesthetic mixture (0.5% bupivacaine 10 ml and 2% lignocaine 10 ml with adrenaline 1 in 200,000)
Number of subjects: 0
Study 6172942 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with 0.05% retinoic acid without occlusion
Number of subjects: 34
Study 6172942 — intervention group
Group type: COMPARATOR
Intervention: Non-HPPK patients
Number of subjects: 34
Study 31049212 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint and physiotherapeutic exercises
Number of subjects: 49
Study 31049212 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapeutic exercises only
Number of subjects: 49
Study 29222136 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored parenting support programme combined with the Connect parenting programme for 12 weeks (1-2 hours per week)
Number of subjects: 120
Study 25285468 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated nitric oxide lozenge (70mg)
Number of subjects: 15
Study 25285468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24342530 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation (EPA: 1.67 g EPA + 0.16 g DHA/d; n = 12)
Number of subjects: 33
Study 24342530 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation (DHA: 1.55 g DHA + 0.40 g EPA/d; n = 12)
Number of subjects: 33
Study 24342530 — intervention group
Group type: COMPARATOR
Intervention: ω‐6 PUFA linoleic acid (LA: 2.2 g/d; n = 9)
Number of subjects: 33
Study 22286020 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacetylmorphine (DAM)
Number of subjects: 28
Study 22286020 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 28
Study 20024700 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyalkylimide gel (PAIG) injections at week 0 and 6
Number of subjects: 31
Study 17700439 — intervention group
Group type: EXPERIMENTAL
Intervention: Information arm (booklet providing evidence-based information on common musculoskeletal pain problems)
Number of subjects: 3808
Study 17700439 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and workplace screening arm
Number of subjects: 3808
Study 17700439 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 3808
Study 15362009 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fall risk factors assessment tool
Number of subjects: 82
Study 12368394 — intervention group
Group type: EXPERIMENTAL
Intervention: (n-3) fatty acids (1.5 g daily)
Number of subjects: 42
Study 12368394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10099032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (titrated from 8 to 48 mg/d)
Number of subjects: 12
Study 7862924 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum and patch
Number of subjects: 2
Study 2764865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (16 two-hour sessions over 4 consecutive days)
Number of subjects: 20
Study 2764865 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced treatment (two two-hour sessions per week for eight weeks)
Number of subjects: 20
Study 2764865 — intervention group
Group type: COMPARATOR
Intervention: Both treatment formats
Number of subjects: 20
Study 2764865 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization of treatment effects
Number of subjects: 20
Study 324830 — intervention group
Group type: EXPERIMENTAL
Intervention: Anafranil
Number of subjects: 173
Study 324830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertofran
Number of subjects: 173
Study 324830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Anafranil and Pertofran
Number of subjects: 173
Study 324830 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 173
Study 29992259 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz beta tACS with placebo
Number of subjects: 0
Study 29992259 — intervention group
Group type: COMPARATOR
Intervention: 20 Hz beta tACS with dextromethorphan
Number of subjects: 0
Study 27939035 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of heated egg powder (50 mg/day from 6 to 9 months, 250 mg/day from 9 to 12 months)
Number of subjects: 147
Study 27939035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no egg introduction)
Number of subjects: 147